Has FDA granted an expedited review for Vascepa (icosapent ethyl)?
The information provided doesn’t include any updates on Vascepa’s expedited FDA review status (such as FDA granting or denying the request, or the specific timeline for a decision). To report progress accurately, I’d need the FDA communication or a reliable source that states the current review status.
Where to check the latest status for Vascepa’s expedited FDA review?
If you’re tracking an expedited pathway, the most reliable places to look are:
- FDA’s press releases or Drug Trials Snapshots / approval announcements for the relevant application
- The FDA’s “Drug approvals and databases” pages for the specific supplement or new label/application (so you can see the review milestone dates)
- Public filings from the manufacturer (Amarin) that cite the FDA’s determination and target timelines
What counts as “expedited” in FDA drug review terms?
Users often mean one of several different FDA processes that can shorten timelines. Common ones include:
- Priority Review (shorter action goal date than standard)
- Accelerated approval pathways (tied to surrogate endpoints and confirmatory trials)
- Breakthrough Therapy designation (earlier intensive FDA guidance, not the same as a guaranteed “fast approval”)
- Fast Track / rolling review mechanics (eligibility depends on unmet need and data package)
If you share which designation or application you mean (e.g., a specific supplemental NDA, label expansion, or indication), I can help map what to look for and what typical next milestones are.
If you tell me the indication/application, I can verify the milestone and timeline
To answer “Any progress” with precision, tell me one of the following:
- the exact wording of the request (Priority Review, Fast Track, Breakthrough, Accelerated approval, etc.)
- the indication or proposed label change tied to Vascepa
- the application type or supplement number (if you have it), or a link/article you’re referencing
Then I can summarize the latest public status and what the next FDA step is expected to be.
What I need from you
Paste the article text/link you’re referring to, or provide the designation type and indication. With that, I can summarize the latest update on Vascepa’s expedited FDA review without guessing.